MedTrace Logo

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

NCT02989649 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 593

Last updated 2019-04-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to observe alogliptin and alogliptin fixed-dose combinations (FDCs) utilization patterns, as well as clinical response to treatment with alogliptin or alogliptin FDCs, in standard clinical practice.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Alogliptin

Alogliptin tablets

DRUG

Alogliptin FDC With Pioglitazone

Alogliptin FDC with pioglitazone tablets

DRUG

Alogliptin FDC With Metformin

Alogliptin FDC with metformin tablets

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-22
Primary Completion
2018-01-26
Completion
2018-01-26

Countries

  • China
  • Hong Kong

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02989649 on ClinicalTrials.gov